Foghorn Therapeutics Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Foghorn Therapeutics Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2019 to 2023.
  • Foghorn Therapeutics Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $1.17M, a 1044% increase year-over-year.
  • Foghorn Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $1.78M, a 0.85% increase from 2022.
  • Foghorn Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $1.76M, a 92.1% decline from 2021.
  • Foghorn Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $22.4M, a 89.7% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $1.78M +$15K +0.85% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-07
2022 $1.76M -$20.7M -92.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-07
2021 $22.4M -$195M -89.7% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 $217M +$194M +807% Jan 1, 2020 Dec 31, 2020 10-K/A 2022-08-09
2019 $24M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.